Literature DB >> 17959755

Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media.

Ted E Schutzbank1, Charlene Jarvis, Nicole Kahmann, Katherine Lopez, Marlea Weimer, Aleta Yount.   

Abstract

We compared the performances of the Third Wave Technology Invader method and the Digene Hybrid Capture 2 assay to detect high-risk human papillomaviruses in 87 cervical brushing specimens submitted in Cytyc ThinPrep media. Two different methods for the extraction of DNA from squamous epithelial cells were also evaluated.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17959755      PMCID： PMC2168565          DOI： 10.1128/JCM.01833-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  A systematic review of the role of human papillomavirus testing within a cervical screening programme.

Authors:  J Cuzick; P Sasieni; P Davies; J Adams; C Normand; A Frater; M van Ballegooijen; E van den Akker
Journal:  Health Technol Assess       Date:  1999       Impact factor: 4.014

2.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

3.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.

Authors:  A M de Roda Husman; J M Walboomers; A J van den Brule; C J Meijer; P J Snijders
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

4.  comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.

Authors:  Maaike A P C van Ham; Judith M J E Bakkers; Gonneke K Harbers; Wim G V Quint; Leon F A G Massuger; Willem J G Melchers
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

5.  Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection.

Authors:  A Schneider; D M Zahm; R Kirchmayr; V L Schneider
Journal:  Am J Obstet Gynecol       Date:  1996-05       Impact factor: 8.661

6.  Management of women who test positive for high-risk types of human papillomavirus: the HART study.

Authors:  J Cuzick; A Szarewski; H Cubie; G Hulman; H Kitchener; D Luesley; E McGoogan; U Menon; G Terry; R Edwards; C Brooks; M Desai; C Gie; L Ho; I Jacobs; C Pickles; P Sasieni
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

7.  Human papillomavirus testing in primary cervical screening.

Authors:  J Cuzick; A Szarewski; G Terry; L Ho; A Hanby; P Maddox; M Anderson; G Kocjan; S T Steele; J Guillebaud
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

Review 8.  The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity.

Authors:  Peter J F Snijders; Adriaan J C van den Brule; Chris J L M Meijer
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996

9.  HPV testing in primary screening of older women.

Authors:  J Cuzick; E Beverley; L Ho; G Terry; H Sapper; I Mielzynska; A Lorincz; W K Chan; T Krausz; P Soutter
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women.

Authors:  C Clavel; M Masure; J P Bory; I Putaud; C Mangeonjean; M Lorenzato; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640
View more
  10 in total

Review 1.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Clinical laboratory experience with cervista HPV HR as a function of cytological classification: comparison with retrospective digene HC2 high-risk HPV DNA test data.

Authors:  Brian K Du Chateau; Elizabeth R Schroeder; Erik Munson
Journal:  J Clin Microbiol       Date:  2012-12-19       Impact factor: 5.948

3.  Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.

Authors:  Kenneth E Youens; Gregory A Hosler; Paula J Washington; E Patrick Jenevein; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

4.  Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA.

Authors:  C C Ginocchio; D Barth; F Zhang
Journal:  J Clin Microbiol       Date:  2008-03-26       Impact factor: 5.948

5.  Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.

Authors:  Gulixian Tuerxun; Awaguli Yukesaier; Ling Lu; Kailibinuer Aierken; Patiman Mijiti; Yujie Jiang; Axianguli Abulizi; Yuanyuan Zhang; Guzhanuer Abuduxikuer; Guzhalinuer Abulizi; Hua Li
Journal:  Oncologist       Date:  2016-06-17

6.  Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.

Authors:  Pengming Sun; Yiyi Song; Guanyu Ruan; Xiaodan Mao; Yafang Kang; Binhua Dong; Fen Lin
Journal:  J Gynecol Oncol       Date:  2017-04-25       Impact factor: 4.401

Review 7.  The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.

Authors:  Zheng Hu; Ding Ma
Journal:  Cancer Med       Date:  2018-09-14       Impact factor: 4.452

8.  Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus.

Authors:  Yusun Hwang; Miae Lee
Journal:  Ann Lab Med       Date:  2012-04-18       Impact factor: 3.464

9.  A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.

Authors:  Gerd Boehmer; Lisa Wang; Angelika Iftner; Barbara Holz; Juliane Haedicke; Reinhard von Wasielewski; Peter Martus; Thomas Iftner
Journal:  BMC Infect Dis       Date:  2014-12-09       Impact factor: 3.090

10.  The prevalence of Human Papilloma Virus (HPV) infection in the oligospermic and azoospermic men.

Authors:  Sherko Nasseri; Seyed Hamidreza Monavari; Hossein Keyvani; Bahram Nikkhoo; Rouhollah Vahabpour Roudsari; Mohammad Khazeni
Journal:  Med J Islam Repub Iran       Date:  2015-10-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.